Nothing Special   »   [go: up one dir, main page]

Sabari et al. - Google Patents

A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC PD-L1 EXPRESSION IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC)

Sabari et al.

View PDF
Document ID
4348493305709934449
Author
Sabari J
Rangachari D

External Links

Snippet

Clinical Research Protocol Page 1 CONFIDENTIAL This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as authorized in writing by the study sponsor A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC …
Continue reading at cdn.clinicaltrials.gov (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis

Similar Documents

Publication Publication Date Title
Sabari et al. A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC PD-L1 EXPRESSION IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC)
Russo Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (< 50%) _ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)
Bahce et al. Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Sundahl et al. Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
CONFIDENTIAL et al. A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab
CONFIDENTIAL et al. Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155) IND NUMBER: Pembrolizumab 118,604; Dinaciclib 114,461 EudraCT NUMBER: Not Applicable NCT NUMBER: NCT02684617
Richart et al. Phase 2B single-site, open-label, nonrandomized study evaluating the efficacy of neoadjuvant MK-3475 for unresectable Stage III and unresectable Stage IV melanoma
CONFIDENTIAL et al. Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)(KEYNOTE-199)
CONFIDENTIAL et al. A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine
CONFIDENTIAL et al. A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Borghaei Supported by Merck and Celgene
CONFIDENTIAL et al. A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
CONFIDENTIAL et al. A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+ 5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059).
Leemans Short title NeoNivo EudraCT number 2018-002643-28 Version 9 Date 11-12-2019 Principal investigators C. Willemien Menke-van der Houven van Oordt, MD PhD
Uronis A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients with Gastro-esophageal Cancer
CONFIDENTIAL et al. A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
Vijayvergia GI-087 A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients with Previously Treated Metastatic High Grade Neuroendocrine tumors
CLINICIANS et al. 1500 E. DUARTE ROAD DUARTE, CA 91010 DEPARTMENT OF MEDICAL ONCOLOGY
Mark Awad Biomarkers of response to ipilimumab and nivolumab as first-line therapy for metastatic non-small cell lung cancer (NSCLC): an open-label, single arm phase 2 study Coordinating Center: Dana-Farber Cancer Institute (DFCI)
Mascarenhas et al. PD-1 inhibition in advanced myeloproliferative neoplasms
Tolaney A randomized phase II study of eribulin mesylate with or without pembrolizumab for metastatic hormone receptor positive breast cancer
CONFIDENTIAL et al. A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
CONFIDENTIAL et al. A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC)–(KEYNOTE-086)
Holder et al. Sub-Investigator (s): Developmental Therapeutics Program of Division of Hematology Oncology
Schlom OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy